Alzinova is seeking a CEO to build and lead the organization into a new chapter of growth (in Swedish)

2015-08-17 15:10

Alzinova söker affärsinriktad VD med erfarenhet inom bioteknik

Vi söker omgående en affärsinriktad och entreprenöriell VD med erfarenhet inom bioteknikområdet till Alzinova AB, som bedriver forskning och utveckling av ett nytt läkemedel för behandling av Alzheimers sjukdom – en av våra största folksjukdomar mot vilken effektiv behandling saknas.


EPO intends to grant Alzinova a European patent for the AβCC Peptide Technology

2015-08-11 08:23

The European Patent Office (EPO) has informed Alzinova that it intends to grant the company a European patent for the AβCC PeptideTM Technology. When finally issued, the patent will strengthen Alzinova’s intellectual property pertaining to the AβCC invention, and cover stabilized oligomers as well as their use as therapeutics and screening tools.

This marks the third approval for this patent family, following the issuing of patents in Australia (in 2013) and China (in 2014). It is still pending in other major markets.

Alzinova completes financing round and prepares to go public

2015-08-03 09:00

Alzinova announced today that it has successfully completed a round of issuing of shares to selected investors. The financing round is intended to provide sufficient capital to take the company public while keeping momentum within R&D activities.


VINNOVA supports Alzinova’s vaccine program

2015-06-26 21:38

Sweden’s innovation agency, VINNOVA, has awarded Alzinova a grant from the program “Innovationsprojekt i företag”.


Alzinova welcomes Dr. Björn Löwenadler to the board

2015-06-24 19:26

Alzheimer’s Association 2015 Report: Prevalence in the US 5.3 million, with $226 billion in costs

2015-03-26 08:13

University scientists present data on Alzinova’s ALZ-201 antibody at AD/PD 2015

2015-03-19 13:43

Alzheimer’s Association: Delaying disease onset by 5 years will within a 10-year period prevent 4 million Americans from getting the disease and save $935 billion

2015-03-19 12:45

Research paper: Alzinova technology used to identify protofibril-binding proteins in CSF and plasma

2015-03-11 15:21

A study recently published in ACS Chemical Biology demonstrates the sticky nature of the soluble aggregates of the peptide amyloid-β (Aβ oligomers) believed to be the primary neurodamaging agent in Alzheimer’s disease.


Solid-state NMR model of AβCC oligomers published in Angewandte Chemie

2014-10-09 09:41

Professor Torleif Härd (Swedish University of Agricultural Sciences) and co-workers have published a structural model of AβCC protofibrils in the journal Angewandte Chemie. In this model, which was derived using solid-state NMR data, AβCC peptides are packed into protofibrils as hexameric barrel-like oligomer units. It is available online here.

Meet Alzinova at BIO-Europe 2014

2014-10-09 08:47

Anders Sandberg, COO, will be attending BIO-Europe in Frankfurt, November 3-5. BIO-Europe is the largest biotechnology partnering conference in Europe.

Please use the conference’s PartneringONE system (EBD Group) to request a meeting.